239 related articles for article (PubMed ID: 17351398)
1. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts.
Xie M; Zhou L; Hu T; Yao M
Anticancer Drugs; 2007 Apr; 18(4):459-66. PubMed ID: 17351398
[TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
3. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
4. Prevention of local tumor growth with paclitaxel-loaded microspheres.
Azouz SM; Walpole J; Amirifeli S; Taylor KN; Grinstaff MW; Colson YL
J Thorac Cardiovasc Surg; 2008 May; 135(5):1014-21. PubMed ID: 18455578
[TBL] [Abstract][Full Text] [Related]
5. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth.
Benny O; Duvshani-Eshet M; Cargioli T; Bello L; Bikfalvi A; Carroll RS; Machluf M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):768-76. PubMed ID: 15701867
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of poly(sebacic acid-co-ricinoleic acid) biodegradable delivery system for intratumoral delivery of paclitaxel.
Shikanov A; Vaisman B; Shikanov S; Domb AJ
J Biomed Mater Res A; 2010 Mar; 92(4):1283-91. PubMed ID: 19343769
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Patil Y; Sadhukha T; Ma L; Panyam J
J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
[TBL] [Abstract][Full Text] [Related]
8. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors.
Lu J; Jackson JK; Gleave ME; Burt HM
Cancer Chemother Pharmacol; 2008 May; 61(6):997-1005. PubMed ID: 17701176
[TBL] [Abstract][Full Text] [Related]
9. In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth.
Lee JY; Kim KS; Kang YM; Kim ES; Hwang SJ; Lee HB; Min BH; Kim JH; Kim MS
Int J Pharm; 2010 Jun; 392(1-2):51-6. PubMed ID: 20298770
[TBL] [Abstract][Full Text] [Related]
10. Polymer chemotherapy for head and neck cancer.
Shikani AH; Domb AJ
Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme.
Ong BY; Ranganath SH; Lee LY; Lu F; Lee HS; Sahinidis NV; Wang CH
Biomaterials; 2009 Jun; 30(18):3189-96. PubMed ID: 19285718
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Lapidus RG; Dang W; Rosen DM; Gady AM; Zabelinka Y; O'Meally R; DeWeese TL; Denmeade SR
Prostate; 2004 Feb; 58(3):291-8. PubMed ID: 14743469
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and biodistribution of paclitaxel-loaded microspheres.
Yan F; Tang S; Fu Q
Arzneimittelforschung; 2012 Apr; 62(4):176-80. PubMed ID: 22270845
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.
Moreno D; Zalba S; Navarro I; Tros de Ilarduya C; Garrido MJ
Eur J Pharm Biopharm; 2010 Feb; 74(2):265-74. PubMed ID: 19883755
[TBL] [Abstract][Full Text] [Related]
15. Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres.
Gupte A; Ciftci K
Int J Pharm; 2004 May; 276(1-2):93-106. PubMed ID: 15113618
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
17. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
18. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
Benny O; Menon LG; Ariel G; Goren E; Kim SK; Stewman C; Black PM; Carroll RS; Machluf M
Clin Cancer Res; 2009 Feb; 15(4):1222-31. PubMed ID: 19190128
[TBL] [Abstract][Full Text] [Related]
19. In vitro characteristics of poly(lactic-co-glycolic acid) microspheres incorporating gelatin particles loading basic fibroblast growth factor.
Li SH; Cai SX; Liu B; Ma KW; Wang ZP; Li XK
Acta Pharmacol Sin; 2006 Jun; 27(6):754-9. PubMed ID: 16723096
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres.
Tzafriri AR; Lerner EI; Flashner-Barak M; Hinchcliffe M; Ratner E; Parnas H
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):826-34. PubMed ID: 15701873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
